<DOC>
	<DOCNO>NCT00730821</DOCNO>
	<brief_summary>The primary objective trial determine MTD combination BIBW 2992/BIBF 1120 therapy administer concomitantly 28-day cycle schedule . Secondary objective collection antitumor efficacy data , determination pharmacokinetic parameter BIBF 1120 BIBW 2992 , data allow determination pharmacokinetic influence BIBW 2992 BIBF 1120 vice versa .</brief_summary>
	<brief_title>Phase I BIBW 2992/BIBF 1120 Combination Therapy Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Nintedanib</mesh_term>
	<criteria>1 . Male female patient confirm diagnosis advance , nonresectable and/or metastatic solid tumor , fail conventional treatment , therapy proven efficacy exists , amenable establish form treatment . 2 . Age 18 year old . 3 . Life expectancy least three ( 3 ) month . 4 . Written inform consent consistent ICHGCP guideline . 5 . Eastern Cooperative Oncology Group performance score 0 , 1or 2 . 6 . Patients recover therapyrelated toxicity previous chemo , hormone , immuno , radiotherapy CTC &lt; = Grade 1 . 7 . Patients must recover previous surgery . 1 . Active infectious disease . 2 . Gastrointestinal disorder may interfere absorption study drug chronic diarrhea . 3 . Serious illness concomitant nononcological disease consider investigator incompatible protocol . 4 . Patients untreated symptomatic brain metastasis . Patients treat , asymptomatic brain metastasis eligible change brain disease status least four ( 4 ) week , history cerebral edema bleed past four ( 4 ) week requirement steroid antiepileptic therapy . 5 . Cardiac leave ventricular function rest ejection fraction &lt; 50 % . 6 . Absolute neutrophil count ( ANC ) less 1500/mm3 . 7 . Platelet count less 100,000/mm3 . 8 . Bilirubin great 1.5 mg/dl ( &gt; 26 ¿mol /L , SI unit equivalent ) . 9 . Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) great two half time upper limit normal ( 2.5 X ULN ) . 10 . Serum creatinine great 1.5 mg/dl ( &gt; 132 ¿mol/L , SI unit equivalent ) . 11 . Women men sexually active unwilling use medically acceptable method contraception . 12 . Pregnancy breastfeed . 13 . Treatment investigational drug ; chemotherapy , immunotherapy , radiotherapy hormone therapy ( include LHRH agonist , megestrol acetate , hormone take breast cancer prostate cancer ) ; participation another clinical study within past 4 week start therapy concomitantly study . Treatment bisphosphonates allow . 14 . Treatment EGFR HER2 inhibit drug within past 4 week start therapy concomitantly study ( 2 week trastuzumab ) . 15 . Patients unable comply protocol . 16 . Active alcohol drug abuse . 17 . Patients require therapeutic anticoagulation antiplatelet therapy [ except treatment Aspirin ( Acetylsalicylic Acid ) ] . 18 . Patients history haemorrhagic thrombotic event ( include transient ischemic attack ) past 12 month . Known inherited predisposition bleed thrombosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>